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Abstract
Hypertension is a very common disorder. It is a major risk factor of myocardial infarction, heart failure, stroke and renal 
failure. It is well known that the immune system also contributes to this disease. Numerous investigations have demon-
strated that lymphocytes are important participants in the development of hypertension and consequent end-organ 
damage. They produce different cytokines such as tumor necrosis factor a, interferon γ, and interleukin 6 that lead 
to the development of hypertension. On the other hand, they are also the source of anti-inflammatory interleukin 10. 
A better knowledge of immunology would lead to the discovery of new therapeutic interventions and more successful 
treatment of our patients.
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Introduction
Hypertension is a very common cardiovascular disease that 
has a significant impact on public health. It affects around 
30% of patients in Europe and the United States. In Poland, 
according to the RYZYKO programme, 36.8% of patients 
suffer from the disease. The prevalence of hypertension 
increases with age, and with our ageing society will pose 
an ever-increasing challenge [1].
Although the diagnostics and treatment of hypertension 
are still developing, its pathomechanism remains unclear. 
The role of the kidneys, the central nervous system and 
the vascular system is widely acknowledged. It is also 
well known that low-grade inflammation contributes to 
numerous cardiovascular diseases, including hypertension.
The concept of immune system contribution to hyper-
tension was first set out in the 1960s, when investigators 
demonstrated that immunosuppression decreased hy-
pertension in a model of renal infarction. Moreover, the 
transfer of lymphocytes from rats with renal infarction 
induced hypertension in animals with previously normal 
blood pressure [2]. Later, it was found that hypertension 
was not observed in thymectomised mice or in athymic 
nude mice with renal infarction [3]. Twenty years later, Ba 
et al. [4] observed that the transplantation of a thymus 
from a Wistar-Kyoto rat to a spontaneously hypertensive 
(SHR) rat resulted in a blood pressure decrease in the 
SHR animal.
More than a decade ago, Guzik et al. [5] demonstra-
ted that hypertension induced by angiotensin II (Ang II) 
or deoxycorticosterone acetate (DOCA-salt) is blunted in 
mice without recombinase-activating gene 1 (Rag1) la-
cking functional lymphocytes. The recombinase activating 
genes 1 and 2 are responsible for recombination of the 
genetic sequences encoding immunoglobulins and the 
T-cell receptor. The authors suggested that either T- or 
B-cells mediate hypertension. Rag1–/– mice did not exhibit 
elevated vascular superoxide production and endothelial 
364
Folia Cardiologica 2019, vol. 14, no. 4
www.journals.viamedica.pl/folia_cardiologica
dysfunction. The hypertensive response can be restored 
by adoptive transfer of lymphocytes T- but not B-cells [6]. 
Also, T-cells were shown to accumulate in the perivascular 
adipose tissue of the aorta. To support the role of T-cells in 
the development of hypertension, Crowley et al. [7] showed 
that mice with severe immunodeficiency were protected 
against hypertension and exhibited reduced renal damage 
and albuminuria.
Blood pressure elevation is moderated by different fac-
tors. The influence of the immune system on hypertension 
is a complex interplay between immune cells, oxidative 
stress, Ang II, low-grade inflammatory state, and the central 
nervous system.
Central nervous system
Vasculature, kidneys and the central nervous system are 
involved in the regulation of blood pressure. It’s worth 
highlighting that T-cells can represent a link between the-
se tissues because lymphoid tissue is rich in sympathetic 
nerves [8].
The circumventricular organs (CVO) can be influenced 
by circulating hormones such as Ang II due to its rich vas-
culature and incomplete blood-brain barrier. What’s more, 
the CVO, and especially the subfornical organ (SFO), play an 
important role in both sending and receiving central signals 
that regulate cardiovascular function and electrolyte balan-
ce [9]. By the deletion of extracellular superoxide dysmutase 
(ecSOD) it became possible to create a model to determine 
the role of central oxidative stress in hypertension. The ab-
sence of ecSOD resulted in elevation of reactive oxygen spe-
cies (ROS) levels in the CVO, and hypertension. In addition, 
when animals with extracellular SOD depletion in the CVO 
were given Ang II at doses that do not cause hypertension 
in normal mice, significant blood pressure elevation was 
observed. This was also accompanied by T-cell infiltration 
around the aorta. When the investigation with ecSOD deple-
tion was repeated using smooth muscles, no hypertension 
and no T-cell response were observed [10–12].
When discussing the role of the central nervous system, 
it’s worth mentioning that lesions in the anteroventral third 
cerebral ventricle, a region where the SFO is situated, can 
prevent Ang II-induced hypertension. And the described 
lesions protect against T-cell activation and aortic infiltra-
tion in reaction to Ang II infusion. This demonstrates that 
Ang II infusion-dependent T-cell activation is caused by 
central signals, rather than by the direct actions of Ang II 
on T-cells [13, 14].
On the other hand, peripheral mechanisms seem to con-
tribute to T-cell activation and vascular inflammation. T-cells 
have been also shown to contribute to stress-induced blood 
pressure elevation [9].
During the progression of hypertension, immune cells 
accumulate in the kidneys and vasculature. These tissues 
produce multiple cytokines that affect vascular and renal 
function. Blood pressure elevation results in a significant 
change in the expression of tumor necrosis factor α (TNF-α), 
IFN-γ, interleukin 6 (IL-6), interleukin 17 (IL-17) and inter-
leukin 10 (IL-10) [6].
Adipose tissue
Obesity is one of the strongest risk factors of hypertension, 
and is associated with low-grade inflammation state, vas-
cular remodelling and endothelial dysfunction.
Adipose tissue is a compound of numerous cells, 
including adipocytes, endothelial cells, fibroblasts, pre-
adipocytes, stem cells and immune cells. Immune cells 
are a source of multiple anti-inflammatory cytokines, for 
example IL-10 and transforming growth factor β (TGF-β). 
They increase insulin sensitivity and protect from inflam-
mation and adipose tissue dysfunction.
In hypertension, perivascular adipose tissue (pVAT) 
inflammation is involved in the pathogenesis of vascular 
dysfunction. Inflammation results in a loss of the protective 
properties of pVAT, a loss of endothelium-dependent vaso-
dilatation, and an increase in vasoconstriction. Functional 
changes within adipose tissue are associated with a change 
in its paracrine and endocrine properties. Decreased re-
lease of protective factors such as adiponectin, nitric acid 
and prostaglandins, and increased pathological adipokine 
release (resistin and visfatin), can be observed. Increased 
production of chemokines such as IP-10 (CXCL10) or RAN-
TES results in the activation of T cells and macrophages. 
Hypertension is associated with immune cells infiltration 
which mediates endothelial dysfunction. Infiltrating im-
mune cells release cytokines such as interleukin 17A 
(IL-17A), IFN-g, TNF-a, and IL-6 which modulate smooth 
muscle cell constriction, proliferation and migration [15].
End-organ damage
The cells of the innate and adaptive immune system 
contribute to end-organ damage in hypertension. An accu-
mulation of T-cells and monocyte/macrophages in vessels 
and the kidneys can be observed. The vascular accumula-
tion is predominantly in the adventitia and the perivascular 
adipose tissue. In the kidneys, T-cell concentration can 
be observed both in the medulla and the renal cortex. As 
mentioned before, these cells produce potent cytokines 
affecting vascular and renal function [16].
IL-17 contributes to numerous autoimmune diseases 
including psoriasis, asthma, Crohn’s disease and rheumatoid 
arthritis. Recently, its role in the development of hypertension 
has been described. McMaster et al. [16] found that angioten-
sin II infusions increased IL-17A production in mouse T cells, 
and that plasma concentrations of IL-17A are increased in 
patients suffering from hypertension. Interestingly, animals 
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lacking IL-17A develop milder hypertension and do not deve-
lop endothelial dysfunction in response to Ang II infusion. The 
conclusions of the authors were that IL-17A might coordinate 
an inflammatory response in hypertension [17, 18].
In addition, it has been recently discovered that this cy-
tokine plays an important role in aortic stiffness. In normal 
conditions, the aorta expands during systole and dilatates 
during diastole. Ang II and DOCA-salt-induced hypertension 
lead to a significant deposition of collagen in the adventitia, 
and as a result to a marked loss of aortic compliance. This 
process does not affect Rag1–/– mice and is restored by the 
adoptive transfer of T-cells to the mice [19].
IL-6 is produced by numerous cells such as macropha-
ges, monocytes, T cells and vascular cells. Elevated con-
centrations of IL-6 correlate with increased blood pressure. 
What is more, a reduction of IL-6 can be observed after 
treatment with Ang II blockade [16].
Increased levels of IFN-γ have been found in hyperten-
sive mice. However, its effect can be different in response 
to different hypertensive stimuli. Subcutaneous injections 
of IFN-γ attenuate hypertension, proteinuria and glomerular 
damage in Dahl-salt-sensitive rats, but does not have any 
effect on spontaneously hypertensive rats. Moreover, mice 
lacking the IFN-γ gene exhibit exaggerated left ventricular 
hypertrophy and worse diastolic dysfunction. Markó et al. 
[20] investigated the role of IFN-γ using mice lacking IFN-γ 
receptor 1. These animals developed less renal fibrosis 
and maintained glomerular rate. And they demonstrated 
reductions in cardiac fibronectin and collagen and less 
frequent arrhythmias than have been observed in wild-type 
mice undergoing Ang II infusion [20, 21].
TNF-α is produced by different cells such as T cells, 
macrophages, endothelial cells, neuronal cells, adipocy-
tes and fibroblasts. Hypertension is associated with an 
elevation of TNF-α concentration. TNF-α activates reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase and nuclear factor κB (NF-κB), which contribute to 
the induction of oxidative stress and as a result chemokine 
and adhesion molecule expression, vascular remodelling, 
and sodium retention by the kidneys. TNF-α also has an 
influence on endothelial nitric oxide production [22, 23].
T regulatory cells
Although T cells are known to contribute to hypertension 
development, the role of specific subsets of T cells and 
their cytokines should be discussed.
The main role of Tregs is the maintenance of immuno-
logical tolerance and they have been found to be involved 
in the pathogenesis of numerous cardiovascular diseases. 
The impairment of Treg cells function or number might 
be involved in different autoimmune and inflammatory 
diseases, such as atherosclerosis, systemic lupus erythe-
matosus, diabetes type 1 and many others [24].
T regulatory cells play an important protective role 
in vascular dysfunction induced by hypertension. They 
are thought to exert their anti-inflammatory function 
by influencing the production of IL-10. IL-10 is a potent 
anti-inflammatory factor, acting through IL-6 and TNF-α 
suppression and has a cardiovascular protective role in 
blood pressure elevation [25].
Radwan et al. [26] were the first to determine that the 
transfer of Treg cells before the development of hyperten-
sion prevented hypertension and vascular dysfunction in 
mice undergoing Ang II infusions. In their recent study, they 
found that established hypertension reduced the number 
of Treg cells by autophagy dysfunction and apoptosis me-
chanisms. Treg cells transferred into a mouse with induced 
hypertension rescued the microvascular function indepen-
dently of arterial pressure-lowering effects. The inhibition 
of autophagy also improved the microvascular function 
independently of arterial blood pressure [26]. As described 
by many authors, Treg cells replacement by infusion could 
be an important new therapeutic strategy for the treatment 
of cardiovascular diseases [24–26].
Gut microbiota
Many investigations have indicated that a reduction in 
gut microbiota is associated with systemic inflammation 
and hypertension [27]. However, the mechanism has not 
been clearly explained yet. Specific immunomodulatory 
effects have been demonstrated using the Bacteroides 
fragilis. Polysaccharides produced by this bacterium 
are able to restore the Th1/Th2 balance in a germ-free 
animal model and affect natural killer cells [28]. Lacto-
bacilli, on the other hand, are able to produce peptides 
that inhibit angiotensin-converting enzyme (ACE) [29]. 
Interestingly, dysbiosis was found in patients suffering 
from hypertension compared to their healthy counter-
parts. The administration of probiotics resulted in mild 
blood pressure reduction [30, 31]. However, the definite 
interaction of gut microbiota and hypertension need to 
be further confirmed.
Conclusions
Hypertension is a disease with a substantial impact on 
public health, resulting in stroke, heart failure and kidney 
disease. Defining the role of the immune system in hyper-
tension could provide new insights into the pathomecha-
nism of this disease, and could help to identify novel targets 
for the treatment of hypertension.
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Streszczenie
Nadciśnienie tętnicze pozostaje w czołówce najczęstszych chorób. Jest głównym czynnikiem ryzyka zawału serca, nie-
wydolności serca, udaru i niewydolności nerek. Od dawna wiadomo, że układ odpornościowy przyczynia się do rozwoju 
tego schorzenia. W wielu badaniach potwierdzono, że limfocyty pełnią kluczową rolę w rozwoju nadciśnienia tętniczego 
i w konsekwencji — powikłań narządowych. Komórki te stanowią źródło licznych cytokin. Wzrost ciśnienia tętniczego 
jest związany z podwyższeniem stężeń cytokin prozapalnych, takich jak: czynnik martwicy nowotworu α, interferon γ, 
interleukina 6, interleukina 17, oraz obniżeniem stężeń cytokin przeciwzapalnych, na przykład interleukiny 10. Dokładne 
poznanie roli układu odpornościowego w nadciśnieniu tętniczym może zaowocować wprowadzeniem nowych strategii 
terapeutycznych i skuteczne leczenie pacjentów.
Słowa kluczowe: nadciśnienie tętnicze, układ odpornościowy, limfocyty
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